One each said mucosal melanoma or PD-L1 negative status should prompt combination therapy, two stated that single-agent PD-1 therapy should always be favored, and 10 panelists felt that a number of other factors should be considered, including medical co-morbidities (e.g. autoimmune disease, history of organ transplantation, etc.), disease volume/tumor burden, site of disease, performance status, functional status, and patient preference. The gene discussed is CD274; the disease is autoimmune disease.